DETECTION AND CLINICAL SIGNIFICANCE OF MICRORNA IN OVARIAN CANCER
10.3969/j.issn.1671-332X.2014.07.030
- VernacularTitle:卵巢恶性肿瘤组织中微小 RNA 的检测及其临床意义
- Author:
Qunfang YANG
;
Weiling YAN
- Publication Type:Journal Article
- Keywords:
Ovarian malignant tumor;
MiR-10a;
Metastasis;
Prognosis
- From:
Modern Hospital
2014;(7):72-75
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the expressions of miR-10a, miR-93 and miR-200a in malignant ovarian tumor tissues and their clinical significances.Methods Real-time quantitative PCR was used to detect the expression of 40 cases of normal ovarian tissue, 40 cases of benign ovarian cyst and 40 cases of miR-10a, miR-93 and miR-200a in malignant ovarian tumor tissues.Analysis of variance and t-Test were respectively applied to compare the expression of miR in different tissues and analyze the correlation between miR and clinicopathological characteristics of malignant ovarian tumor .Kaplan-Meier Log-rank test and Cox proportional hazards regression model were adopted in prognosis.Results The expression lev-els of miR-10a in ovarian cancer tissues were significantly higher than that in benign ovarian tumor tissues and normal ovari-an tissues (p<0.001), whereas the expression of miR-93 and miR-200a in the three types of tissues was no statistically significant difference (p>0.05).The expression quantity of miR-10a in malignant ovarian tumor tissues with greater omen-tum metastasis, lymph node metastasis and distant organ metastasis was significantly higher than that without metastasis ( p<0.05).The median survival time of patients with higher expression of miR -10a was lower than that of patients with low ex-pression of miR-10a (p=0.01).Multi-factor Cox model analysis showed that the expression quantity of miR -10a was an independent factor affecting survival prognosis in patients(p=0.002).Conclusion Our data suggest that miR-10a is asso-ciated with ovarian cancer metastasis, which is the main factor affecting prognosis in ovarian cancer.It might serve as a bio-marker for judging the prognosis in ovarian cancer.
